^
Association details:
| Biomarker: | EML4_E20-ALK_E19 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib
Excerpt:
Another patient, a 24‐year old woman administered crizotinib as a second‐line regimen, developed intracranial progression within one month. The baseline lymph node was detected as Ventana immunohistochemistry‐positive and the NGS results of baseline blood plasma showed a TP53 mutation concurrent with EML4_E20:ALK_E19 fusion
DOI:
10.1111/1759-7714.13071
